NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ANRO Stock Alerts $14.18 +0.05 (+0.35%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$13.94▼$14.1850-Day Range$12.96▼$17.9052-Week Range$12.78▼$24.00Volume22,746 shsAverage Volume105,750 shsMarket Capitalization$381.16 millionP/E RatioN/ADividend YieldN/APrice Target$32.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Alto Neuroscience alerts: Email Address Alto Neuroscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.0% Upside$32.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 3 Articles This WeekInsider TradingAcquiring Shares$9.70 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.05) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector479th out of 913 stocksPharmaceutical Preparations Industry211th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingAlto Neuroscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlto Neuroscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ANRO. Previous Next 0.0 Dividend Strength Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANRO. Previous Next 1.8 News and Social Media Coverage News SentimentAlto Neuroscience has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alto Neuroscience this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,700,614.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.05) to ($2.53) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Alto Neuroscience Stock (NYSE:ANRO)Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Read More ANRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANRO Stock News HeadlinesApril 2, 2024 | insidertrades.comAlto Neuroscience, Inc. (NYSE:ANRO) CFO Purchases $100,614.00 in StockApril 24, 2024 | americanbankingnews.comAlto Neuroscience (NYSE:ANRO) Shares Up 1.8%April 28, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 23, 2024 | markets.businessinsider.comTreatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry LandscapeApril 23, 2024 | businesswire.comAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaApril 3, 2024 | finance.yahoo.comAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid FinancialsMarch 25, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)April 28, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Alto Neuroscience’s Promising Clinical Trials Signal Market PotentialMarch 21, 2024 | businesswire.comAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 11, 2024 | finance.yahoo.comAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlto Neuroscience to Participate in Upcoming Investor ConferencesFebruary 27, 2024 | uk.investing.comAnalysts bullish on Alto NeuroscienceFebruary 27, 2024 | msn.comStifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming dataFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience Amid Promising Precision Neuropsychiatric TreatmentsFebruary 27, 2024 | businesswire.comAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 13, 2024 | morningstar.comAlto Neuroscience Inc ANROFebruary 13, 2024 | uk.investing.comAlto Neuroscience Inc (ANRO)February 13, 2024 | cnn.comAlto Neuroscience, Inc.February 12, 2024 | finance.yahoo.comAlto Neuroscience, Inc. (ANRO)February 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Pricing of Upsized Initial Public OfferingFebruary 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesSee More Headlines Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)6/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CUSIPN/A CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$32.33 High Stock Price Target$33.00 Low Stock Price Target$32.00 Potential Upside/Downside+128.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio15.22 Quick Ratio15.22 Sales & Book Value Annual Sales$210,000.00 Price / Sales1,815.04 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares26,880,000Free FloatN/AMarket Cap$381.16 million OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Amit Etkin M.D. (Age 47)Ph.D., Founder, Chairman of the Board, CEO & President Comp: $705.65kMr. Nicholas C. Smith (Age 35)CFO & Secretary Comp: $624.12kMr. Adam Savitz M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $579.57kMr. Dan Segal B.Sc. (Hons) (Age 62)BCom, CA, MSc, Co-Founder & Special Advisor to the CEO Mr. Wei Wu Ph.D. (Age 41)Co-Founder & Chief Data Science Officer Ms. Melissa Berman (Age 44)Vice President of Finance & Accounting Ms. Erin R. McQuade J.D. (Age 49)General Counsel & Chief Administrative Officer Ms. Jessica Powell (Age 49)Chief Development Officer Mr. Fadi Abdel M.D. (Age 45)Senior Vice President of Innovation More ExecutivesKey CompetitorsNeurogeneNASDAQ:NGNEPepGenNASDAQ:PEPGBiomea FusionNASDAQ:BMEAHarrow HealthNASDAQ:HROWLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsidersNicholas Conrad SmithBought 6,150 shares on 3/28/2024Total: $100,614.00 ($16.36/share)Wave Global Lp AlphaBought 600,000 shares on 2/6/2024Total: $9.60 M ($16.00/share)View All Insider Transactions ANRO Stock Analysis - Frequently Asked Questions Should I buy or sell Alto Neuroscience stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alto Neuroscience in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANRO shares. View ANRO analyst ratings or view top-rated stocks. What is Alto Neuroscience's stock price target for 2024? 5 analysts have issued 12 month target prices for Alto Neuroscience's shares. Their ANRO share price targets range from $32.00 to $33.00. On average, they predict the company's share price to reach $32.33 in the next year. This suggests a possible upside of 128.0% from the stock's current price. View analysts price targets for ANRO or view top-rated stocks among Wall Street analysts. How have ANRO shares performed in 2024? Alto Neuroscience's stock was trading at $21.80 at the beginning of 2024. Since then, ANRO stock has decreased by 35.0% and is now trading at $14.18. View the best growth stocks for 2024 here. When is Alto Neuroscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 20th 2024. View our ANRO earnings forecast. What ETF holds Alto Neuroscience's stock? iShares Neuroscience and Healthcare ETF holds 1,308 shares of ANRO stock, representing 0.51% of its portfolio. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $16.00 per share. When did Alto Neuroscience's quiet period expire? Alto Neuroscience's quiet period expired on Wednesday, March 13th. Alto Neuroscience had issued 8,040,000 shares in its public offering on February 2nd. The total size of the offering was $128,640,000 based on an initial share price of $16.00. During Alto Neuroscience's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ANRO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
